Evidence map›Paper›PMID 29959634›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2018

Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.

Takashi Suzuki, Satoshi Yajima, Nobuki Ishioka, Tatsuki Nanami, Yoko Oshima, Naohiro Washizawa, Kimihiko Funahashi, Seiko Otsuka, Tetsuo Nemoto, Hideaki Shimada

Abstract read
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Comparison between a new assay system, ElecsysMolecular and clinical oncology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2019
    Article
  20. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Takashi SuzukiDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Satoshi YajimaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Nobuki IshiokaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Tatsuki NanamiDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Yoko OshimaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Naohiro WashizawaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Kimihiko FunahashiDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Seiko OtsukaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan.
Tetsuo NemotoDepartment of Pathology, School of Medicine, Toho University, Tokyo, Japan.
Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 142-8541, Japan. hideaki.shimada@med.toho-u.ac.jp.ORCID 0000-0002-1990-8217
Toho University · JP

Funding

JSPS KAKENHI JP16K10520
6 · The paper itself

Abstract

backgroundThe p53 protein overexpression that usually results from genetic alterations reportedly induces serum antibodies against p53. However, little information is available about the prognostic significance of perioperative serum p53 antibody (s-p53-Abs) titers in patients with esophageal squamous cell carcinoma.

methodsIn this study, we retrospectively evaluated the clinical significance of perioperative s-p53-Abs in 135 patients with esophageal squamous cell carcinoma. Of these, 58 patients received neoadjuvant chemotherapy comprising 5-FU and CDDP. While the cutoff level at 1.3 U/ml indicated seropositive patients, level of 13.4 U/ml was used to identify high-titer patients. We monitored serum titers seropositive patients after surgery and evaluated the prognostic significance by the univariate and multivariate analyses.

resultsIn this study, 29 patients (21.5%) were positive for s-p53-Abs before treatment. The frequency of both seropositive patients and high-titer patients (> 13.4 U/ml) was not significantly associated with tumor progression. While seropositive patients did not demonstrate significant poor overall survival, high-titer patients demonstrated significant poor overall survival based on the multivariate analysis (P < 0.001). Moreover, the s-p53-Abs titer did not correlate with the response to neoadjuvant chemotherapy. Among seropositive patients, the negative conversion of s-p53-Abs more likely led to be long-term survival.

conclusionsThis study determined that the high-titer of s-p53-Abs was an independent risk factor to reduce the overall survival of patients with esophageal cancer patients. The negative conversion of s-p53-Abs could be a good indicator of favorable prognosis.

Indexed as

AdultAgedAged, 80 and overAntibodies, NeoplasmBiomarkers, TumorDisease-Free SurvivalEsophageal Squamous Cell CarcinomaFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPerioperative PeriodPrognosisRetrospective StudiesRisk FactorsAntibodies, NeoplasmBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53Esophageal squamous cell carcinomaPrognosisSerum p53 antibodySerum titer

Identifiers

PMID29959634
OpenAlexW2810434459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.